GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells October 3, 2019
GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics September 24, 2019
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial September 12, 2019
GT Biopharma GTB-1550 PHASE I-II Results to be Published in Conjunction With 2019 ASCO Meeting May 31 - June 4 in Chicago May 29, 2019
